Bimekizumab is associated with significant complete clearance rates at 4 years among patients with scalp, nail, or palmoplantar psoriasis.

Please provide your email address to receive an email when new articles are posted on . Patients with palmoplantar plaque-type psoriasis had significantly improved signs and symptoms of disease when ...

—In Israel, researchers recently examined which of several common comorbidities were more likely to occur in patients with palmoplantar plaque psoriasis. One in particular was unexpected. Plaque ...

A literature review in JAAD identified several drugs most effective in clearing palmoplantar psoriasis. None were effective in clearing palmoplantar pustulosis. A total of 15 studies reported that ...

Data from the phase 2 LEDA trial demonstrated that sonelokimab treatment led to meaningful improvements in patients with PPP. The Food and Drug Administration (FDA) has granted Fast Track designation ...

A systematic review of biologics used in to treat palmoplantar psoriasis and palmoplantar pustulosis, 2 diseases that affect the palms and the soles of feet, found several available biologics are at ...

Please provide your email address to receive an email when new articles are posted on . None of the patients with palmoplantar plaque psoriasis achieved PASI 75 or PASI 90. 37.5% of those patients ...

Researchers reviewed data on 330 children and youths aged 0–18 years who had received a primary psoriasis diagnosis and who were seen at an academic pediatric dermatology clinic from 2012 to 2022.

VIENNA — For patients with moderate to severe palmoplantar plaque psoriasis, improvements were significantly better at 2 weeks with ixekizumab (Taltz, Lilly) than with etanercept or placebo, according ...

Compared with White patients, Black male patients had a higher prevalence of palmoplantar psoriasis, according to one study. When examining risk factors associated with palmoplantar psoriasis (PP), ...

MoonLake Immunotherapeutics has announced the initiation of new trials for sonelokimab, an investigational Nanobody® aimed at treating inflammatory diseases. The Phase 3 VELA-TEEN trial will evaluate ...